Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$43.52 USD
+0.67 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $43.47 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
RNA 43.52 +0.67(1.55%)
Will RNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNA
Company News for Aug 13, 2024
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Other News for RNA
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
These are the stocks with the largest changes in short interest in July - GS
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating with New Price Objective